Corrigendum to

Leong, P. Y., W. C. Chuang, J. L. Ko, et al. 2026. “A Probiotic Combination of Limosilactobacillus reuteri and Clostridium butyricum Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis in Rats by Strengthening Barrier Integrity and Modulating Immuno-Microbial Homeostasis.” Journal of Cellular Physiology 241, no. 5: e70183. doi/10.1002/jcp.70183 In Section 2.3 (Probiotic Strain and Mixture Preparation) of the Materials and Methods section, the description of Clostridium butyricum MIYAIRI 588 was incomplete. The text: C. butyricum MIYAIRI 588 (CBM588), originally isolated from a soil sample in Japan in 1963 and developed as a pharmaceutical-grade probiotic (Isa et al. 2016), was purchased as a lyophilized powder from Miyarisan Pharmaceutical Co. (Nagano, Japan) via Asia Bio-Med Management Limited (Taichung, Taiwan). Should have read: C. butyricum MIYAIRI 588 (CBM588), originally isolated from a soil sample in Japan in 1963 and developed as a pharmaceutical-grade probiotic (Isa et al. 2016), was obtained in the form of Miyarisan BM (manufactured by Miyarisan Pharmaceutical Co., Ltd., Tokyo, Japan). In addition, the text: In contrast, C. butyricum MIYAIRI 588 was reconstituted directly from the pharmaceutical-grade lyophilized powder in PBS (pH 7.2) without prior subculturing. Should have read: In contrast, C. butyricum MIYAIRI 588 was prepared directly from the commercial finished product in PBS (pH 7.2) without prior subculturing. We apologize for this error.